Figure 6.

Effects of the surface-charged tripterine-loaded NLCs on tumor growth in vivo. (A) Representative images of tumors excised from C57BL/6 mice: (i) control (negative control); (ii) tripterine; (iii) cationic NLCs; (iv) neutral NLCs; (v) anionic NLCs; (vi) cyclophosphamide (CTX; 20 mg/kg intraperitoneally; positive control). In (ii–v), 6 mg/kg tripterine in 1% carbomer gel was used and the treatments were administered topically. (B) Tumor weight; (C) tumor inhibition rate after accounting for tumor weight.

Notes: Data represent means ± SD (n = 3); *P < 0.05 and **P < 0.01 versus the controls.

Abbreviation: NLCs, nanostructured lipid carriers.